gastrointestinal ulcer, reflux esophagitis, chronic constipation, ulcerative colitis , Crohn'
Conditions
Interventions
None listed
Sponsors
EA Pharma Co.,Ltd.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients registered with Medilead Healthcare Panel (MHP) who have answers at the survey on December 2019 (past survey) 2. Patients who reported in- or outpatient visits for gastrointestinal diseases within 1 year before the past survey 3. Patients who reported gastrointestinal diseases (gastrointestinal ulcer, reflux esophagitis, chronic constipation, ulcerative colitis , Crohn's disease, and hepatic cirrhosis)
Exclusion criteria
Exclusion criteria: 1. Patients who did not report any use of drugs for gastrointestinal diseases at the past survey 2. Patients who reported any cancer at the past survey 3. Patients who work for any of the following organizations - market research companies - media companies - advertising companies - hospitals or clinics - pharmaceutical companies - pharmaceutical wholesalers 4. Patients whose family members work for any of the above organizations
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The interval, amount, and days of prescriptions for medications of gastrointestinal diseases | — |
Secondary
| Measure | Time frame |
|---|---|
| EQ-5D J-HLS-EU-Q47 Adherence scale for patients with chronic disease | — |
Countries
Japan
Contacts
Public ContactHisanori Masaki
EA Pharma Co.,Ltd. Medical Division
Outcome results
None listed